0001104659-21-024408.txt : 20210216 0001104659-21-024408.hdr.sgml : 20210216 20210216172705 ACCESSION NUMBER: 0001104659-21-024408 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Hunter C CENTRAL INDEX KEY: 0001636385 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 21641062 MAIL ADDRESS: STREET 1: C/O GENESEE & WYOMING INC. STREET 2: 20 WEST AVENUE CITY: DARIEN STATE: CT ZIP: 06820 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm216849-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-02-11 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001636385 Smith Hunter C 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Financial Officer Restricted Stock Units 2021-02-11 4 A 0 9375 0 A Common Stock 9375 9375 D Stock Option (Right to Buy) 30.66 2021-02-11 4 A 0 56250 0 A 2031-02-10 Common Stock 56250 56250 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter C. Smith 2021-02-16